Classifica tra le azioni
#40642
Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies... Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies for cancer patients in the United States, specifically addressing challenges like tumor immune evasion and drug resistance. Its diverse oncology pipeline includes CM24, a humanized monoclonal antibody that targets and blocks carcinoembryonic antigen related cell adhesion molecule 1 (CEACAM1). Currently in Phase 2 clinical trials, CM24 is being investigated as a combination therapy with anti-PD-1 checkpoint inhibitors for treating pancreatic ductal adenocarcinoma. Another candidate is NT219, a small molecule compound in Phase 1/2 clinical trials, which functions by inhibiting insulin receptor substrate 1 and 2 (IRS1/2) and signal transducer and activator of transcription (STAT). This compound is being developed for recurrent and/or metastatic squamous cell carcinoma of the head and neck, or colorectal adenocarcinoma. Furthermore, IM1240, a multi-valent antibody designed to activate an anti-tumoral immune response against 5T4-positive tumors, is in its preclinical stage. The company has established significant collaborations, including an agreement with Bristol Myers Squibb Company for Phase 2 clinical trials to assess CM24 in combination with the PD-1 inhibitor nivolumab and chemotherapy, as well as a partnership with Mor Research Applications. Formerly known as Kitov Pharma Ltd., the company adopted the name Purple Biotech Ltd. in December 2020 and is headquartered in Rehovot, Israel.
Prezzo delle azioni
$0.00323826
Ultima sincronizzazione: 2026-08-12
Capitalizzazione di mercato
$104.81K
Variazione (1 giorno)
0.00%
Variazione (1 anno)
-70.42%
Scambia Purple Biotech Ltd. (PPBT)
Margine operativo per Purple Biotech Ltd. (PPBT)
Margine operativo al 2026 TTM: 0.00%
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Purple Biotech Ltd., il margine operativo attuale (TTM) è 0.00%. Alla fine del 2026, il margine operativo era 0.00%.
Storico del margine operativo per Purple Biotech Ltd. da 2026 a 2026
Margine operativo alla fine di ogni anno
| Anno |
Margine Operativo |
Cambia |
|
Non abbastanza dati per le date fornite. |
Margine operativo per aziende simili o concorrenti
| Azienda |
Margine Operativo |
Differenza del margine operativo |
Il paese |
|
|
38.97% |
-
|
US
|
|
|
28.81% |
-
|
NL
|
|
|
0.00% |
-
|
CH
|
|
|
0.00% |
-
|
KR
|
|
|
31.23% |
-
|
BE
|
Cos'è l'Margine operativo di un'azienda?
L'Margine operativo è un indicatore chiave per valutare la redditività di un'azienda. Margini operativi più elevati sono generalmente preferibili poiché indicano che l'azienda riesce a vendere i propri prodotti o servizi a un prezzo significativamente superiore rispetto ai costi di produzione. Si calcola dividendo gli utili per i ricavi.
